Skip to Content
Merck
  • Acceleration of bone regeneration by local application of lithium: Wnt signal-mediated osteoblastogenesis and Wnt signal-independent suppression of osteoclastogenesis.

Acceleration of bone regeneration by local application of lithium: Wnt signal-mediated osteoblastogenesis and Wnt signal-independent suppression of osteoclastogenesis.

Biochemical pharmacology (2014-06-24)
Masaki Arioka, Fumi Takahashi-Yanaga, Masanori Sasaki, Tatsuya Yoshihara, Sachio Morimoto, Masato Hirata, Yoshihide Mori, Toshiyuki Sasaguri
ABSTRACT

Inhibition of glycogen synthase kinase (GSK)-3 and the consequent activation of the Wnt/β-catenin signaling pathway have been reported to increase bone volume. To develop a novel pharmacotherapy for injured bone, we investigated whether GSK-3 inhibitor was effective in promoting bone formation. In in vitro experiments, we examined the effects of GSK-3 inhibitors LiCl and SB216763 on osteoblastogenesis of mesenchymal progenitor C3H10T1/2 cells and osteoclastogenesis of osteoclast precursor RAW-D cells. Both inhibitors promoted osteoblast differentiation, assessed by alkaline phosphatase activity and calcium deposition, stimulating the Wnt/β-catenin signaling pathway and thereby inducing Runx2. On the other hand, the GSK-3 inhibitors suppressed osteoclast differentiation, assessed by tartrate-resistant acid phosphatase staining and number of nuclei in the cells, reducing NFATc1 expression independently of the Wnt/β-catenin signaling pathway. In subsequently performed in vivo studies, we examined the effect of locally administered Li2CO3 on the recovery from a partial defect made on the rat tibia. Computerized tomography and bone histomorphometry showed that Li2CO3 accelerated bone regeneration in defect lesion with increased lamellar bone ratio compared with the controls. These results suggested that local application of lithium (or other GSK-3 inhibitors) might effectively facilitate recovery from bone injury by promoting osteoblastogenesis and inhibiting osteoclastogenesis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lithium chloride, AnhydroBeads, −10 mesh, 99.998% trace metals basis
Sigma-Aldrich
Lithium-7Li chloride, 99 atom % 7Li, 99% (CP)
Sigma-Aldrich
Lithium chloride, AnhydroBeads, −10 mesh, ≥99.9% trace metals basis
Supelco
Lithium chloride solution, 1 M in ethanol
Sigma-Aldrich
NGF-β human, from human, recombinant, expressed in NSO cells, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe, ≥97% (HPLC)
Sigma-Aldrich
Lithium chloride, for molecular biology, ≥99%
Sigma-Aldrich
Lithium chloride solution, 8 M, for molecular biology, ≥99%
Sigma-Aldrich
4′,6-Diamidino-2-phenylindole dihydrochloride, powder, BioReagent, suitable for cell culture, ≥98% (HPLC and TLC), suitable for fluorescence
Sigma-Aldrich
Lithium chloride, powder, ≥99.98% trace metals basis
Sigma-Aldrich
4′,6-Diamidino-2-phenylindole dihydrochloride, suitable for fluorescence, BioReagent, ≥95.0% (HPLC)
Sigma-Aldrich
Lithium chloride, BioXtra, ≥99.0% (titration)
Sigma-Aldrich
Lithium chloride, BioUltra, for molecular biology, anhydrous, ≥99.0% (AT)
Sigma-Aldrich
Lithium chloride, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
Sigma-Aldrich
Lithium chloride, puriss. p.a., anhydrous, ≥99.0% (AT)
Sigma-Aldrich
Lithium chloride, ACS reagent, ≥99%
Sigma-Aldrich
Lithium chloride, ReagentPlus®, 99%
Sigma-Aldrich
Lithium chloride, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, 99%
Supelco
Electrolyte solution, nonaqueous, LiCl in ethanol (saturated)
Sigma-Aldrich
Calcein, Used for the fluorometric determination of calcium and EDTA titration of calcium in the presence of magnesium.
Supelco
Electrolyte solution, nonaqueous, 2 M LiCl in ethanol